BSE Live
Mar 12, 16:00Prev. Close
28.76
Open Price
28.70
Bid Price (Qty.)
28.30 (250)
Offer Price (Qty.)
29.33 (100)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Rekvina Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.01 | 0.07 | 0.05 | 0.05 | -0.03 | |
| Diluted EPS (Rs.) | 0.01 | 0.07 | 0.05 | 0.05 | -0.03 | |
| Cash EPS (Rs.) | 0.01 | 0.07 | 0.06 | 0.05 | -0.03 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 0.93 | 2.26 | 2.19 | 2.13 | 2.08 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 0.93 | 2.26 | 2.19 | 2.13 | 2.08 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.05 | 0.26 | 0.26 | 0.27 | 0.00 | |
| PBDIT/Share (Rs.) | 0.01 | 0.09 | 0.07 | 0.10 | -0.03 | |
| PBIT/Share (Rs.) | 0.01 | 0.09 | 0.07 | 0.10 | -0.03 | |
| PBT/Share (Rs.) | 0.01 | 0.09 | 0.07 | 0.05 | -0.03 | |
| Net Profit/Share (Rs.) | 0.01 | 0.07 | 0.06 | 0.05 | -0.03 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 15.28 | 35.79 | 26.23 | 38.54 | 0.00 | |
| PBIT Margin (%) | 15.28 | 35.79 | 26.23 | 38.54 | 0.00 | |
| PBT Margin (%) | 14.95 | 35.79 | 26.09 | 19.50 | 0.00 | |
| Net Profit Margin (%) | 12.18 | 28.84 | 21.20 | 19.50 | 0.00 | |
| Return on Networth / Equity (%) | 0.71 | 3.28 | 2.57 | 2.46 | -1.28 | |
| Return on Capital Employed (%) | 0.71 | 3.28 | 2.57 | 2.46 | -1.28 | |
| Return on Assets (%) | 0.60 | 2.90 | 2.33 | 2.40 | -1.27 | |
| Total Debt/Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 4.97 | 10.06 | 11.00 | 12.30 | 0.00 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 4.34 | 4.57 | 5.53 | 16.61 | 63.86 | |
| Quick Ratio (X) | 4.34 | 4.57 | 5.53 | 16.61 | 63.86 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 7.85 | 5.03 | 1.57 | 1.57 | 1.57 | |
| EV/Net Operating Revenue (X) | 239.27 | 64.73 | 19.63 | 19.29 | 0.00 | |
| EV/EBITDA (X) | 1,565.61 | 180.86 | 74.83 | 50.05 | -194.54 | |
| MarketCap/Net Operating Revenue (X) | 239.10 | 64.79 | 19.67 | 19.33 | 0.00 | |
| Retention Ratios (%) | 0.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Price/BV (X) | 13.97 | 7.39 | 2.38 | 2.45 | 2.51 | |
| Price/Net Operating Revenue | 240.93 | 64.98 | 19.73 | 19.37 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
10.03.2026
Astal Lab Standalone December 2025 Net Sales at Rs 52.24 crore, up 261.27% Y-o-Y
09.03.2026
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
06.03.2026
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities